STOCK TITAN

Senseonics - SENS STOCK NEWS

Welcome to our dedicated page for Senseonics news (Ticker: SENS), a resource for investors and traders seeking the latest updates and insights on Senseonics stock.

Senseonics Holdings, Inc. (symbol: SENS) is a pioneering medical technology firm based in Germantown, Maryland. The company's primary focus is on developing and commercializing advanced glucose monitoring systems that significantly improve the lives of people managing diabetes. Utilizing cutting-edge fluorescence sensing technology, Senseonics has designed the Eversense Continuous Glucose Monitoring (CGM) System, recognized for being the first fully implantable CGM system. This system comprises a tiny sensor implanted under the skin, an external smart transmitter, and a user-friendly mobile application, allowing for real-time glucose monitoring without the need for a dedicated receiver.

The Eversense CGM System stands out for its accuracy and stability throughout its extended sensor life, offering continuous glucose monitoring for up to 180 days. This long-term solution provides an alternative to traditional short-term CGMs, catering to individuals who require a more stable and reliable glucose monitoring option.

Senseonics has established strong partnerships, including a notable collaboration with Ascensia Diabetes Care, which ensures that their innovative solutions reach a global audience. Their latest product, the Eversense E3 CGM System, is part of an extended assistance program known as the Eversense Payment Assistance and Simple Savings (PASS) Program. This program offers eligible individuals in the U.S. the opportunity to access the Eversense E3 systems at a significantly reduced out-of-pocket cost of $99 for each six-month period, thereby making continuous glucose monitoring more affordable.

Senseonics is committed to advancing diabetes management technology, as evidenced by their continued innovation and dedication to improving accessibility to their products. The company's forward-looking approach and strategic alliances position them as a key player in the medical technology landscape, specifically in the context of diabetes management.

Rhea-AI Summary
Senseonics Holdings, Inc. (SENS) will release its Q4 and full year 2023 financial results on February 29, 2024. A conference call will be held to review the performance, with a webcast available on the company's website. Investors and analysts can dial in to listen.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.07%
Tags
-
Rhea-AI Summary
Ascensia Diabetes Care and Senseonics Holdings, Inc. announce Medicare expansion for Eversense E3 CGM System, providing access to all people with diabetes using insulin and non-insulin users with hypoglycemia history. The Eversense E3 offers unique features like up to 6-month sensor wear duration, high accuracy, removable transmitter, and predictive alerts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.34%
Tags
none
-
Rhea-AI Summary
PHC Holdings Corporation and Senseonics Holdings, Inc. announced the appointment of Brian Hansen as President of CGM at Ascensia Diabetes Care, reinforcing their commitment to diabetes innovation. Hansen will be responsible for global commercialization and growth of the Eversense CGM, offering unique features such as a fully implantable system, long-term glucose measurement, and a removable smart transmitter. The partnership aims to drive patient and provider adoption of Eversense, with a focus on delivering breakthrough diabetes devices to empower people living with diabetes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.52%
Tags
management
Rhea-AI Summary
Senseonics Holdings, Inc. (SENS) announces operational and financial business updates, including preliminary unaudited fourth quarter revenue of $8.0 million and full year 2023 total revenue of $22.0 million. The company completed data analysis of ENHANCE trial and plans to submit an application for regulatory approval to the FDA for a 365-day once per week calibration product by the end of the first quarter of 2024. The company also closed an additional $10.0 million draw on the loan facility with Hercules Capital, Inc. in the fourth quarter, with unaudited balance of cash, cash equivalents, and marketable securities as of December 31, 2023, expected to be approximately $109.8 million. The company expects to provide financial guidance for 2024 with the full fiscal year 2023 financial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.29%
Tags
none
-
Rhea-AI Summary
Senseonics Holdings, Inc. (NYSE American: SENS) reported Q3 2023 financial results, including $6.1M in revenue, completion of a pivotal clinical study, and a new advertising campaign. Gross profit increased to $1.2M, while net loss decreased to $24.1M. The company expects full year 2023 global net revenue to be in the range of $20M to $24M.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.95%
Tags
-
Rhea-AI Summary
Senseonics Holdings, Inc. (SENS) to Participate in Stifel 2023 Healthcare Conference, Presenting on Long-Term Implantable CGM Systems for Diabetes Patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.16%
Tags
conferences
Rhea-AI Summary
Senseonics Holdings, Inc. (SENS) plans to release its Q3 2023 financial results on November 9, 2023. The company is focused on the development and manufacturing of long-term, implantable continuous glucose monitoring systems for people with diabetes. A conference call will be held to review the performance, which will be webcasted and archived on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.28%
Tags
-
Rhea-AI Summary
Ascensia Diabetes Care and Senseonics Holdings launch new advertising campaign for Eversense E3 CGM System
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.77%
Tags
none
-
Rhea-AI Summary
Senseonics completes ENHANCE Pivotal Clinical Study for Eversense CGM system, aims for FDA approval for 365-day system
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.65%
Tags
Rhea-AI Summary
Senseonics Holdings, Inc. to present at Gilmartin Group Emerging Growth Company Showcase
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.16%
Tags
conferences acquisition

FAQ

What is the current stock price of Senseonics (SENS)?

The current stock price of Senseonics (SENS) is $0.9611 as of February 21, 2025.

What is the market cap of Senseonics (SENS)?

The market cap of Senseonics (SENS) is approximately 648.9M.

What does Senseonics Holdings, Inc. specialize in?

Senseonics specializes in developing and commercializing advanced glucose monitoring systems for diabetes management, featuring the first fully implantable CGM system.

What is the Eversense Continuous Glucose Monitoring (CGM) System?

The Eversense CGM System is a breakthrough glucose monitoring solution that includes a small sensor implanted under the skin, an external smart transmitter, and a mobile app for real-time glucose data.

How long can the Eversense CGM System monitor glucose levels?

The Eversense CGM System can continuously monitor glucose levels for up to 180 days, offering a long-term solution compared to traditional short-term CGMs.

What is the Eversense Payment Assistance and Simple Savings (PASS) Program?

The PASS Program is designed to make the Eversense E3 CGM System more affordable by offering eligible individuals in the U.S. the system at a reduced cost of $99 for each six-month period.

How does Senseonics' CGM technology benefit people with diabetes?

The CGM technology provides highly accurate, stable, and long-term glucose monitoring, enabling people with diabetes to manage their condition confidently and with ease.

Where is Senseonics Holdings, Inc. headquartered?

Senseonics Holdings, Inc. is headquartered in Germantown, Maryland, USA.

Who are Senseonics' key partners?

Senseonics has key partnerships with companies like Ascensia Diabetes Care, which helps in the global distribution and accessibility of their products.

How can I learn more about the Eversense CGM System?

You can visit Ascensia Diabetes Care's website or contact their support line to get detailed information about the Eversense CGM System and eligibility for the PASS Program.

Is the Eversense CGM System available outside the United States?

Yes, the Eversense CGM System is available globally, and Senseonics generates a significant portion of its revenue from markets outside the United States.

What is the mission of Senseonics Holdings, Inc.?

The mission of Senseonics is to transform the lives of people with diabetes through innovative, long-term implantable glucose management technology.
Senseonics

NYSE:SENS

SENS Rankings

SENS Stock Data

648.91M
563.20M
4.94%
10.03%
8.19%
Medical Devices
Industrial Instruments for Measurement, Display, and Control
Link
United States
GERMANTOWN